Industry
Biotechnology
Alzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001 that is in Phase II clinical trial, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and AL002 that completed preclinical stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.
Loading...
Open
1.48
Mkt cap
6.7M
Volume
83K
High
1.53
P/E Ratio
-0.01
52-wk high
19.20
Low
1.45
Div yield
N/A
52-wk low
1.40
Portfolio Pulse from Benzinga Newsdesk
August 19, 2024 | 1:58 pm
Portfolio Pulse from Avi Kapoor
August 19, 2024 | 1:56 pm
Portfolio Pulse from Benzinga Newsdesk
August 19, 2024 | 1:53 pm
Portfolio Pulse from Benzinga Newsdesk
August 19, 2024 | 1:51 pm
Portfolio Pulse from Benzinga Newsdesk
August 19, 2024 | 1:49 pm
Portfolio Pulse from Vandana Singh
August 19, 2024 | 1:41 pm
Portfolio Pulse from Benzinga Newsdesk
August 19, 2024 | 12:36 pm
Portfolio Pulse from Benzinga Newsdesk
August 19, 2024 | 12:08 pm
Portfolio Pulse from Benzinga Newsdesk
August 19, 2024 | 12:04 pm
Portfolio Pulse from Benzinga Newsdesk
August 12, 2024 | 12:18 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.